Hemorrhagic Fevers (Machupo Virus - Arenaviruses)
Overview
Plain-Language Overview
Hemorrhagic fevers caused by Machupo virus, a member of the Arenaviridae family, are severe viral illnesses that primarily affect the blood vessels and the body's ability to control bleeding. These infections lead to widespread damage to the vascular system, causing symptoms like fever, bleeding, and shock. The virus is transmitted to humans through contact with infected rodents or their excreta, mainly in certain regions of South America. The disease can rapidly progress to life-threatening complications due to vascular leakage and organ failure. Early symptoms often resemble common viral infections, but the condition can worsen quickly, affecting multiple organ systems.
Clinical Definition
Machupo virus hemorrhagic fever is a severe systemic illness caused by the Machupo virus, an arenavirus transmitted primarily through exposure to infected rodent excreta. The core pathology involves endothelial cell damage leading to increased vascular permeability, resulting in hemorrhage, hypovolemia, and shock. The disease is characterized by an initial febrile phase followed by hemorrhagic manifestations such as petechiae, mucosal bleeding, and internal bleeding. Neurological symptoms may also occur in severe cases. The infection is endemic to specific regions in Bolivia and is a significant cause of viral hemorrhagic fever in South America. Diagnosis and management are critical due to the high mortality associated with severe cases.
Inciting Event
Inhalation or contact with aerosolized rodent urine or feces contaminated with Machupo virus.
Direct contact with broken skin or mucous membranes exposed to infected rodent secretions.
Handling or consumption of contaminated food or water in endemic areas.
Person-to-person transmission via bodily fluids is rare but possible in healthcare settings.
Latency Period
The incubation period typically ranges from 7 to 14 days after exposure.
Symptoms usually develop within 1 to 2 weeks following contact with the virus.
Latency can be as short as 5 days or as long as 21 days in some cases.
Diagnostic Delay
Early symptoms are nonspecific and flu-like, leading to misdiagnosis as common viral illnesses.
Limited availability of specific serologic or PCR testing in endemic regions delays confirmation.
Overlap with other hemorrhagic fevers such as Bolivian hemorrhagic fever complicates clinical recognition.
Lack of awareness among healthcare providers about Machupo virus epidemiology contributes to missed diagnosis.
Clinical Presentation
Signs & Symptoms
High fever and severe malaise during the initial phase
Hemorrhagic manifestations including petechiae, ecchymoses, and mucosal bleeding
Severe headache and myalgia
Gastrointestinal symptoms such as vomiting and diarrhea
Neurologic symptoms including confusion and seizures in advanced disease
History of Present Illness
Initial presentation includes fever, malaise, headache, and myalgia lasting several days.
Progression to facial and conjunctival edema, hemorrhagic manifestations such as petechiae and bleeding gums occurs.
Patients may develop hypotension, shock, and neurological symptoms including confusion and seizures.
Severe cases show rapid deterioration with multi-organ failure and coma.
Past Medical History
Previous exposure to rodents or endemic environments increases suspicion for Machupo virus infection.
History of immunosuppression or chronic illness may worsen disease severity.
No specific prior medical conditions are required but lack of vaccination or prophylaxis is relevant.
Prior episodes of hemorrhagic fever or viral infections may be noted in endemic populations.
Family History
No known heritable predisposition or familial syndromes are associated with Machupo virus infection.
Family members may share common environmental exposures in endemic areas.
Clusters of cases can occur in households due to shared rodent exposure but not genetic transmission.
No documented genetic susceptibility loci have been identified for arenavirus hemorrhagic fevers.
Physical Exam Findings
Petechiae and purpura due to capillary fragility and thrombocytopenia
Conjunctival injection and ocular hemorrhages
Lymphadenopathy and hepatosplenomegaly in some cases
Hypotension and signs of shock in severe hemorrhagic phases
Mucosal bleeding including gingival and nasal hemorrhages
Diagnostic Workup
Diagnostic Criteria
Diagnosis is established by detecting Machupo virus RNA using RT-PCR or isolating the virus in cell culture from blood samples during the acute phase. Serologic testing for IgM and IgG antibodies against Machupo virus can support diagnosis, especially in later stages. Clinical suspicion is based on a compatible febrile hemorrhagic illness with epidemiologic exposure to endemic areas and rodent contact. Laboratory findings often include thrombocytopenia, elevated liver enzymes, and evidence of coagulopathy. Confirmatory diagnosis relies on molecular or serologic testing performed in specialized reference laboratories.
Pathophysiology
Key Mechanisms
Infection with Machupo virus, an Arenavirus, leads to widespread endothelial cell damage causing increased vascular permeability and hemorrhagic manifestations.
Immune dysregulation with impaired antiviral response contributes to systemic viral dissemination and cytokine storm.
Coagulopathy results from consumption of clotting factors and platelet dysfunction, promoting bleeding.
Direct viral replication in monocytes and macrophages exacerbates tissue injury and systemic inflammation.
Capillary leak syndrome causes hypovolemia and shock, which are major contributors to mortality.
| Involvement | Details |
|---|---|
| Organs | Liver involvement leads to impaired synthesis of clotting factors, exacerbating bleeding tendencies. |
Spleen is a site of viral replication and immune cell depletion, contributing to immunosuppression. | |
Kidneys may be affected by hypoperfusion and contribute to multi-organ failure in severe cases. | |
| Tissues | Vascular endothelium is critically damaged by viral infection and immune-mediated injury, leading to hemorrhage and shock. |
Lymphoid tissue shows depletion and dysfunction contributing to impaired immune responses. | |
| Cells | Macrophages serve as primary target cells for Machupo virus replication and contribute to systemic viral dissemination. |
Endothelial cells are infected leading to vascular damage and increased permeability causing hemorrhagic symptoms. | |
Dendritic cells are involved in antigen presentation but may be functionally impaired during infection. | |
| Chemical Mediators | Cytokines such as TNF-alpha and IL-6 are elevated and mediate systemic inflammation and vascular leakage. |
Interferons are part of the innate antiviral response but are often insufficient to control viral replication. | |
Platelet-activating factor contributes to endothelial dysfunction and hemorrhagic manifestations. |
Treatments
Pharmacological Treatments
Ribavirin
- Mechanism:
Inhibits viral RNA synthesis by acting as a nucleoside analog, impairing replication of arenaviruses including Machupo virus.
- Side effects:
Hemolytic anemia
Teratogenicity
Elevated liver enzymes
- Clinical role:
First-line
Non-pharmacological Treatments
Provide aggressive supportive care including fluid resuscitation and electrolyte management to prevent shock.
Implement strict isolation and barrier precautions to prevent nosocomial transmission of Machupo virus.
Monitor and manage bleeding complications with blood product transfusions as needed.
Prevention
Pharmacological Prevention
Ribavirin has shown some efficacy in early treatment and post-exposure prophylaxis
No widely available vaccine for Machupo virus currently exists
Experimental antiviral agents under investigation for Arenavirus infections
Non-pharmacological Prevention
Rodent control to reduce exposure to infected Calomys species
Avoidance of contact with rodent excreta in endemic areas
Use of personal protective equipment (PPE) for healthcare workers
Isolation and barrier nursing of infected patients to prevent nosocomial spread
Public health education on transmission and hygiene measures
Outcome & Complications
Complications
Hypovolemic shock from severe hemorrhage
Multi-organ failure including hepatic and renal dysfunction
Disseminated intravascular coagulation (DIC)
Neurologic complications such as encephalitis
Death in severe untreated cases
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Hemorrhagic Fevers (Machupo Virus - Arenaviruses) versus Ebola Virus Disease
Hemorrhagic Fevers (Machupo Virus - Arenaviruses) | Ebola Virus Disease |
|---|---|
Exposure to rodents in rural Bolivia or other South American regions | Contact with infected primates or bats in Central and West Africa |
Arenavirus family, ambisense single-stranded RNA virus | Filovirus family, negative-sense single-stranded RNA virus |
Variable severity with hemorrhagic manifestations developing over 1-3 weeks | Rapid progression with high fatality often within 7-10 days |
Hemorrhagic Fevers (Machupo Virus - Arenaviruses) versus Lassa Fever
Hemorrhagic Fevers (Machupo Virus - Arenaviruses) | Lassa Fever |
|---|---|
Exposure to Calomys rodents in Bolivia and surrounding areas | Exposure to Mastomys rats in West Africa |
Machupo virus, an arenavirus endemic to Bolivia | Lassa virus, an arenavirus endemic to West Africa |
Thrombocytopenia with prominent hemorrhagic diathesis and vascular leakage | Elevated liver enzymes and thrombocytopenia common |
Hemorrhagic Fevers (Machupo Virus - Arenaviruses) versus Dengue Hemorrhagic Fever
Hemorrhagic Fevers (Machupo Virus - Arenaviruses) | Dengue Hemorrhagic Fever |
|---|---|
Rodent exposure in rural South American regions | Mosquito bite exposure in tropical and subtropical urban areas worldwide |
Arenavirus transmitted by rodent excreta | Flavivirus transmitted by Aedes mosquitoes |
Hemorrhagic fever with progressive bleeding and neurological symptoms over 1-3 weeks | Febrile illness with plasma leakage and shock typically after 3-7 days |
Hemorrhagic Fevers (Machupo Virus - Arenaviruses) versus Yellow Fever
Hemorrhagic Fevers (Machupo Virus - Arenaviruses) | Yellow Fever |
|---|---|
Exposure to rodent reservoirs in rural Bolivia | Exposure in tropical Africa or South America via mosquito bites |
Arenavirus causing hemorrhagic fever without predominant hepatic necrosis | Flavivirus causing hepatic necrosis and jaundice |
Moderate liver enzyme elevation with prominent thrombocytopenia and hemorrhage | Marked elevation of transaminases and bilirubin |
Hemorrhagic Fevers (Machupo Virus - Arenaviruses) versus Crimean-Congo Hemorrhagic Fever
Hemorrhagic Fevers (Machupo Virus - Arenaviruses) | Crimean-Congo Hemorrhagic Fever |
|---|---|
Rodent exposure in South American endemic areas | Tick bite exposure in Africa, Asia, and Eastern Europe |
Arenavirus transmitted by rodent excreta | Nairovirus transmitted by Hyalomma ticks |
Subacute hemorrhagic fever with neurological involvement over 1-3 weeks | Rapid onset hemorrhagic fever with high mortality within 1-2 weeks |